Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Motif Bio PLC    MTFB   GB00BVVT4H71

MOTIF BIO PLC (MTFB)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 11:35:08 am
39.7 GBp   +0.44%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
41.5(c) 40.5(c) 38(c) 39.525(c) 39.7(c) Last
4 459 797 2 463 411 928 987 679 333 1 072 563 Volume
+6.41% -2.41% -6.17% +4.01% +0.44% Change
More quotes
Financials (GBP)
Sales 2018 -
EBIT 2018 -20,8 M
Net income 2018 -
Debt 2018 14,4 M
Yield 2018 -
Sales 2019 16,0 M
EBIT 2019 -1,96 M
Net income 2019 -
Debt 2019 13,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 8,28x
Capitalization 119 M
More Financials
Company
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The... 
More about the company
Latest news on MOTIF BIO PLC
2018Motif Bio to participate at upcoming Jefferies London Healthcare Conference
GL
2018MOTIF BIO : Presents New Iclaprim Data at IDWeek
AQ
2018MOTIF BIO : Presents New Iclaprim Data at IDWeek
AQ
2018Motif Bio Presents New Iclaprim Data at IDWeek
GL
2018AMPHION INNOVATIONS : Motif Bio plc - Motif Bio Notes Statement from Amphion Inn..
AQ
2018MOTIF BIO : Reports Half-Year 2018 Financial Results and Operational Progress
AQ
2018Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
GL
2018Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
GL
2018MOTIF BIO : Presents Iclaprim Data at ESCMID/ASM Conference
AQ
2018MOTIF BIO : Antibiotic for skin condition granted Priority Review by FDA
AQ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart MOTIF BIO PLC
Duration : Period :
Motif Bio PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOTIF BIO PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,04  GBP
Spread / Average Target 161%
EPS Revisions
Managers
NameTitle
Graham George Lumsden Chief Executive Officer & Executive Director
Richard Cecil Eversfield Morgan Non-Executive Chairman
Jonathan E. Gold Chief Financial Officer & Executive Director
David B. Huang Chief Medical Officer
Rajesh B. Shukla Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MOTIF BIO PLC26.63%153
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300